References
- Berg A.T., Shinnar S.: The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology, 1991, 41: 965–972.
- Bromley R.L., Mawer G., Love J., Kelly J., Purdy L., McEwan L., Liverpool and Manchester Neurodevelopment Group [LMNDG].: Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia, 2010, 51: 2058–2065. doi: 10.1111/j.1528-1167.2010.02668.x.
- Chen Z., Brodie M., Liew D., Kwan P.: Treatment outcomes in patients with newly diagnosed epilepsy treated with established antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol., 2018, 75: 279–286.
- Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia, 1981, 22: 489–501.
- De Boer H., Mula M., Sander J.W.: The global burden and stigma of epilepsy. Epilepsy Behav., 2008, 12: 540–546.
- Devinsky O., Cross J.H., Laux L., Marsh E., Miller I., Nabbout R., et al.: Trial of cannabidiol for drug-resistant seizures in the Dravet Syndrome. N. Engl. J. Med., 2017, 376: 2011–2020. doi: 10.1056/NEJMoa1611618.
- European Medicines Agency: New measures to avoid valproate exposure in pregnancy. EMA/145600/2018. https://www.ema.europa.eu/documents/preelease/new-measures-avoid-valproate-exposure-pregnancy-endorsed_en.
- Fisher R.S., van Emde Boas W., Blume W., Elger C., Genton P., Lee P., Engel J. Jr.: Epileptic seizure and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia, 2005, 46: 470–472.
- Fisher R.S., Acevedo C., Arzimanoglou A., Bogacz A., Cross J.H., Elger C.E. et al.: ILAE oficial report: a practical clinical definition of epilepsy. Epilepsia, 2014, 55: 475–482.
- Fisher R.S., Cross J.H., French J.A., Higurashi N., Hirsch E., Jansen F.E. et al.: Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017a, 58: 522–530. doi: 10.1111/epi.13670
- Fisher R.S., Cross J.H., D’Souza C., French J.A., Haut S.R., Higurashi N. et al.: Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia, 2017b, 58: 531–542. doi: 10.1111/epi.13671.
- French J.A., Kanner A.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L. et al.: Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia, 2004a, 45: 401–409.
- French J.A., Kanner A.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L. et al.: Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 2004b, 62: 1261–1273.
- Glauser T., Ben-Menachem E., Bourgeois B., Cnaan A., Chadwick D., Guerreiro C. et al.: ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia, 2006, 47: 1094–1120.
- Harden C.L., Maroof A., Nikolov B., Fowler K., Sperling M., Liporace J. et al.: The effect of seizure severity on quality of life in epilepsy. Epilepsy Behav., 2007, 11: 208–211. doi. org/10.1016/j.yebeh.2007.05.002.
- Hauser W.A., Rich S.S., Lee J.R., Annegers J.F., Anderson V.E.: Risk of recurrent seizures after two unprovoked seizures. N. Engl. J. Med., 1998, 338: 429–434.
- Hesdorffer D.C., Benn E.K., Cascino G.D., Hauser W.A.: Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia, 2009, 50: 1102–1108.
- Jędrzejczak J., Majkowska-Zwolińska B., Ryglewicz D.: Zalecenia Polskiego Towarzystwa Epileptologii dotyczące leczenia napadów padaczkowych u dorosłych. Journal of Epileptology, 2014, 22 (Suppl. 2): 3–11.
- Kanner A.M., Ashman E., Gloss D., Harden C., Bourgeois B., Bautista J.F. et al.: Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 2018a, 91: 82–90. doi: 10.1212/WNL.0000000000005756.
- Kanner A.M., Ashman E., Gloss D., Harden C., Bourgeois B., Bautista J.F. et al.: Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the American Epilepsy Society and the Guideline. Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Epilepsy Curr., 2018b, 18: 269–278. doi: 10.5698/1535-7597.18.4.269.
- Majkowska-Zwolińska B., Majkowski J., Kaciński M., Kaczyńska-Haładyj M.: Przewlekłe schorzenia współwystępujące u osób z padaczką. Epileptologia, 2008, 16: 5–25.
- Majkowska-Zwolińska B., Jędrzejczak J., Majkowski J.: Clinical use of concommitant medicines in epileptic patients in Poland: a 12 month prospective multicentre study. Seizure, 2011, 20: 673–678.
- Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M. and NEAD Study Group: Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med., 2009, 360: 1597–1605. doi: 10.1056/NEJMoa0803531.
- Mula M., Cock H.R.: More than seizures: improving the lives of people with refractory epilepsy. Eur. J. Neurol., 2015, 22: 24–30.
- NICE, 2004; 2018. www.nice.org.uk/guidance/cg137
- Patsalos P.N., Froscher W., Pisani F., van Rijn C.: The importance of drug interactions in epilepsy therapy. Epilepsia, 2002, 43: 365–385.
- SIGN, 2003. www.sign.ac.uk/sign-143-diagnosis-and-management-of-epilepsy-in-adults.
- Tellez-Zenteno J.F., Matijevic S., Wiebe S.: Somatic comorbidity of epilepsy in the general population in Canada. Epilepsia, 2005, 46: 1955–1962.
- Tellez-Zenteno J.F., Patten S.B., Jette N., Williams J., Wiebe S.: Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia, 2007, 48: 2336–2344.
- Thiele, E.A., Marsh, E.D., French, J.A., Mazurkiewicz, M.B., Benbadis, S.R., Joshi, C. and GWPCARE4 Study Group.: Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 2018, 391: 1085–1096.
- Villanueva V., López F.J., Serratosa J.M., González-Giraldez B., Campos D., Molins A. et al: Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide. Epilepsy Behav., 2013, 29: 349–356. doi: 10.1016/j.yebeh.2013.07.024.
- Villanueva V., Garcés M., López-Gomáriz E., Serratosa J.M., González-Giráldez B., Parra J. and REALLY Study Group.: Early add-on lacosamide in a real-life setting: results of the REALLY study. Clin. Drug Investig., 2015, 35: 121–131. doi: 10.1007/s40261-014-0255-5.
- Weston J., Bromley R., Jackson C.F., Adab N., Clayton-Smith J., Greenhalgh J. et al.: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst. Rev., 2016, 11: CD010224.
- Zadeh W.W., Escartin A., Byrnes W., Tennigkeit F., Borghs S., Li T. and SP0954 Study Group: Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial. Seizure, 2015, 31: 72–79. doi: 10.1016/j.seizure.2015.07.001.